Share this story:

Ventripoint JV Begins Training Chinese Cardiologists in Heart Analysis System and Achieves Milestone of First Commercial Sales





Toronto, Ontario – TheNewswire – March 2, 2021 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce that its partner, Yutian Medical Shanghai Inc. (“Yutian”), has reported a successful engagement with key opinion leaders in the echocardiography sector in China.  A training session in the use of the QAS™ (VMS™ in China) has been conducted in China for approximately 60 echocardiologists.  The session was offered in cooperation with one of the leading University Hospitals in China and organized by the China Medical Association, Intensive Care Division. The training included advanced techniques for right-ventricular quantitative analysis using 2D ultrasound, and the approach of the QAS to using artificial Intelligence (AI) to analyze all studies including lower quality images where only sparse data were available.

In addition, Yutian has appointed tier-1 distributors in major regions throughout China and has already signed agreements with minimum sales targets totaling 30 million RMB (~$6M Canadian) for 2021 from this initial group of distributors. Yutian is continuing to expand the distribution network in China and reports the first commercial sale to a tier-1 hospital in China.

About Cardiovascular Disease (CVD) in China

Heart disease is the leading cause of death worldwide -- accounting for approximately one-third of deaths in 2019.  China had the highest number of heart disease deaths, followed by India, Russia, the United States and Indonesia (1).  China is rapidly aging due to a birth boom during the 1950s to 1970s, which was followed by a long period of imposed 1 child policy (2). Currently, >16% of the population is age 60 years or more, and this proportion is projected to increase to 35% by 2050. The combination of population growth and aging are expected to contribute at least another 3.4 million deaths from CVD over the next 2 decades, and related costs are projected to increase by USD $7.8 trillion from 2012 to 2030 (2).

China has twice the rate of hypertension and cardiac mortality as the United States due to known risk factors.  This latest review paper (1) recommended “risk reduction for avoiding dangerous patterns of alcohol consumption, preventing smoking, adopting diets low in added sugar, sodium, and harmful fats, and maintaining a healthy weight beginning early in life. Effective and affordable clinical strategies remain overlooked by health systems as targets for investments, including methods for non-invasive screening.”

There are 34,000 hospitals in China and 1,000 new hospitals being built each year.  The rate of admissions for CVD in China is almost twice that of  the United States and Europe, as China has not been as successful in changing people’s habits and thus provides critical cardiac care (2).

  1. (1) Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: J Am Coll Cardiol. 2020, Dec, 76 (25) 2982-3021) 

  2. (2)Epidemiology of Cardiovascular Disease in China and Opportunities for Improvement: J Am Coll Cardiol2019, Jun, 73 (24) 3135–3147 

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Dr. George Adams

Email: gadams@ventripoint.com

Phone: 519-803-6937‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends'' and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.